Literature DB >> 83189

Isoprinosine: an overview.

L N Simon, A J Glasky.   

Abstract

Isoprinosine appears to have a relatively low degree of both acute and chronic toxicity in both rodent and nonrodent species. Preclinical studies have demonstrated that isoprinosine can inhibit the growth of both DNA and RNA viruses as well as potentiate cell-mediated immune response both in vitro and in vivo. Clinical studies with rhinovirus, herpesvirus, and influenza virus infections in man demonstrated that isoprinosine treatment reduced clinical symptoms and enhanced certain cell-mediated immune responses compared to placebo-treated controls.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 83189

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Suppression of frequently recurring genital herpes: acyclovir v inosine pranobex.

Authors:  A Mindel; O Carney; C Sonnex; M Freris; G Patou; P Williams
Journal:  Genitourin Med       Date:  1989-04

2.  Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.

Authors:  S Araki; K Kagaya; K Kitoh; M Kimura; Y Fukazawa
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

Review 3.  Ribavirin and inosiplex: a review of their present status in viral diseases.

Authors:  T W Chang; R C Heel
Journal:  Drugs       Date:  1981-08       Impact factor: 9.546

Review 4.  Inosine pranobex. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.

Authors:  D M Campoli-Richards; E M Sorkin; R C Heel
Journal:  Drugs       Date:  1986-11       Impact factor: 9.546

Review 5.  Inosine Pranobex: A Key Player in the Game Against a Wide Range of Viral Infections and Non-Infectious Diseases.

Authors:  Jiri Sliva; Chrysoula N Pantzartzi; Martin Votava
Journal:  Adv Ther       Date:  2019-06-05       Impact factor: 3.845

6.  Genotoxicity and Mutagenicity of Inosine Pranobex.

Authors:  Sylwia Tobólska; Sylwia Terpiłowska; Jerzy Jaroszewski; Andrzej Krzysztof Siwicki
Journal:  J Vet Res       Date:  2018-10-24       Impact factor: 1.744

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.